Pfizer's obesity pill news leaves analysts wanting
The New York-based Big Pharma is hoping to recover from earlier data that showed a twice-daily formulation of oral danuglipron led to modest weight loss with a HIGH LEVEL OF ADVERSE EVENTS AND PATIENT DISCONTINUATIONS.
Now, the company is looking to advance the med as a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.
SUMMARY:
Lab Technician: "The bloody thing is not working, participant's are getting really sick and pulling out of the trials"
Albert Bourla: "Make it work, fudge the figures, just do what you have to do. We need a slice of the obesity market pie until those Covid Vaccines really kick in, then we'll smash it out of the park with our cancer drugs."
https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering
- Forums
- Breaking News
- COVID AND THE VACCINE - TRUTH, LIES, AND MISCONCEPTIONS REVEALED
Pfizer's obesity pill news leaves analysts wantingThe New...
-
- There are more pages in this discussion • 2,444 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online